EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
about
ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration.Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.Visual outcomes of polypoidal choroidal vasculopathy treated with intravitreal ranibizumab with or without photodynamic therapy.Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom.One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study
P2860
EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
EVEREST study report 3: diagno ...... failures in the EVEREST study
@ast
EVEREST study report 3: diagno ...... failures in the EVEREST study
@en
type
label
EVEREST study report 3: diagno ...... failures in the EVEREST study
@ast
EVEREST study report 3: diagno ...... failures in the EVEREST study
@en
prefLabel
EVEREST study report 3: diagno ...... failures in the EVEREST study
@ast
EVEREST study report 3: diagno ...... failures in the EVEREST study
@en
P2093
P2860
P1476
EVEREST study report 3: diagno ...... failures in the EVEREST study
@en
P2093
Colin S Tan
EVEREST Study Group
Louis W Lim
Nikolle W Tan
Tock H Lim
Wei Kiong Ngo
P2860
P2888
P304
P356
10.1007/S00417-016-3333-Y
P577
2016-05-03T00:00:00Z